Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / COM
-
Number of holders
-
80
-
Total 13F shares, excl. options
-
28.5M
-
Shares change
-
+291K
-
Total reported value, excl. options
-
$841M
-
Value change
-
+$13.2M
-
Number of buys
-
40
-
Number of sells
-
-26
-
Price
-
$29.57
Significant Holders of Jade Biosciences, Inc. - COM (AVTE) as of Q1 2024
84 filings reported holding AVTE - Jade Biosciences, Inc. - COM as of Q1 2024.
Jade Biosciences, Inc. - COM (AVTE) has 80 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28.5M shares
.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (8.26M shares), Sofinnova Investments, Inc. (3.76M shares), TCG Crossover Management, LLC (2.2M shares), Atlas Venture Life Science Advisors, LLC (2.04M shares), BAKER BROS. ADVISORS LP (1.68M shares), Frazier Life Sciences Management, L.P. (1.2M shares), Cormorant Asset Management, LP (1.07M shares), GREAT POINT PARTNERS LLC (888K shares), Driehaus Capital Management LLC (795K shares), and BlackRock Inc. (710K shares).
This table shows the top 80 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.